AllSci News
UC Davis researchers map LSD structure to guide non-hallucinogenic drug design
Researchers at the University of California, Davis have used systematic chemical deconstruction of lysergic acid diethylamide (LSD) to identify which...
Harbour Bio partner Solstice raises USD 225m to advance CTLA-4 antibody in neoadjuvant cancer
Boston-based Solstice Oncology launched with a USD 225 million Series A financing to advance porustobart (HBM4003), an Fc-enhanced CTLA-4 antibody that...
Leyden Labs advances RIG-101 after Phase I shows safety and on-target immune activation
Phase I data from Netherlands-based Leyden Laboratories B.V.'s intranasal innate immune modulator RIG-101 showed acceptable safety and on-target...
Prana reports prolonged Type 2 biomarker suppression with IL-4Rα/TSLP bispecific
Phase I data from a placebo-controlled study in healthy adults suggest that PRA-216, a bispecific antibody that simultaneously blocks IL-4Rα and TSLP, can...
Lancet data show durable responses with PeproMene's BAFF-R CAR T after CD19 CAR T failure
Phase I data for PMB-CT01, a B-cell activating factor receptor (BAFF-R)-targeted autologous chimeric antigen receptor (CAR) T-cell therapy, have been...
Pharvaris’s deucrictibant XR cuts HAE attack rate 83% in Phase III, advancing dual oral strategy
Pharvaris N.V. (Nasdaq: PHVS) has reported an 83% reduction in monthly hereditary angioedema (HAE) attack rate with deucrictibant extended-release (XR)...
Schrödinger spins out Tectora with USD 55m Series A for immunology programs
Schrödinger (Nasdaq: SDGR) has licensed two early-stage small molecule immunology and inflammation programs to Tectora Therapeutics, a newly formed...
Assembly Bio converts HSV program from royalty deal to 40% US profit-share with Gilead
Assembly Biosciences (Nasdaq: ASMB) has exercised its embedded option to co-share 40% of US development costs and profits for the herpes simplex virus (HSV)...
Beam reports durable BEAM-302 AAT restoration, advances pivotal cohort
Updated Phase I/II data from Beam Therapeutics' (Nasdaq: BEAM) BEAM-302 program, presented at the European Respiratory Society Congress in Barcelona, show...
Korsana goes public with USD 380m raise and Alzheimer's antibody poised for Phase I
Waltham, Massachusetts-based Korsana Biosciences (Nasdaq: KRSA) has completed its reverse merger with Cyclerion Therapeutics and closed a USD 380 million...
Evommune's EVO756 suffers second Phase IIb setback in two months with AD miss
California-based Evommune, Inc. (NYSE: EVMN) revealed EVO756, an oral Mas-related G protein-coupled receptor X2 (MRGPRX2) antagonist, failed to meet its...
Insilico's IPF drug rentosertib shows biological age reversal in exploratory proteomic analysis
A new analysis published in Nature Biotechnology adds an unexpected dimension to the clinical profile of rentosertib, the AI-designed TNIK inhibitor from...
Semaglutide clears obesity treatment threshold in children aged 6 to under 12
Phase III data from Novo Nordisk's STEP Young trial show that once-weekly semaglutide (Wegovy, Ozempic, Rybelsus) reduced body mass index (BMI) in children...
Sernova, Seraxis merge to build integrated stem cell islet replacement platform for T1D
Canada-based Sernova Biotherapeutics Inc. (TSX: SVA) and Germantown, Maryland-based Seraxis Holdings, Inc. have signed a definitive merger agreement to...
Cloverleaf Bio lands USD 33m seed with Lilly, AbbVie, and Boehringer backing
Connecticut-based Cloverleaf Bio has raised USD 33 million in an oversubscribed seed financing round to advance a platform of engineered transfer RNA...
The AllSci Brief
Free, systematic R&D and deal news. Daily.